Looking after your vision
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Search
Search results
Frequently asked questions
The following questions are often asked by people contacting Retina UK.
Webinar: Michael Gilhooley, Optogenetics
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Children and young people
Different inherited sight loss conditions present noticeable symptoms at different times.
Improved sensory and auditory function cane tip
If you are a cane user, you may be interested to hear about the new cane tip introduced by Rotacaster that offers improved sensory and auditory feedback, alongside many other features.
Taking on The Thames Path Challenge
Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.
Notice of the forthcoming Retina UK AGM – June 2023
Formal notice of the forthcoming Annual General Meeting in June 2023.
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Light sensing small molecule given green light
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
Sirius clinical trial – Exon 13 mutation of USH2A
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.